key: cord-0898314-j50bbo9p
authors: Machuca, T. N.; Bharat, A.; Kurihara, C.; Jr, R. Garza-Castillon; Kim, S.; Manerikar, A.; Pelaez, A.; Pipkin, M.; Shahmohammadi, A.; Rackauskas, M.; KG, S.; Balakrishnan, K.; Jindal, A.; Schaheen, L.; Hashimi, S.; Bhuddhdev, B.; Arjuna, A.; Rosso, L.; Palleschi, A.; Lang, C.; Jaksch, P.; Nosotti, M.; Hoetzenecker, K.
title: International Experience with Lung Transplantation for COVID-19 Associated Acute Respiratory Distress Syndrome
date: 2021-04-30
journal: The Journal of Heart and Lung Transplantation
DOI: 10.1016/j.healun.2021.01.1765
sha: 6403b2ecba944cf5e35f4d60685729074ceb2446
doc_id: 898314
cord_uid: j50bbo9p

Purpose The COVID-19 pandemic has infected millions of people across the world and caused several thousands of deaths. Given advances in extracorporeal life support technology, ECMO for COVID-19 acute respiratory distress syndrome (ARDS) has proven to be successful in sustaining life, however, has left a significant number of patients fully depended on devices and incapable of being weaned. Lung transplantation, as a well-established therapy for end-stage lung disease, has been considered for some patients with COVID-19 ARDS in the absence of lung recovery and the presence of findings suggestive of end-stage lung disease. Methods This is an International collaborative effort to assess the role of lung transplantation in COVID-19 ARDS. There is worldwide representation with centers from US (3), Europe (2) and Asia (1). Patients with COVID-19 ARDS supported on ECMO and/or mechanical ventilation who were deemed unweanable and developed features of end-stage lung disease were evaluated for lung transplantation. We followed ISHLT conventional recipient selection criteria recommendations and a 2 negative COVID-19 PCRs from bronchoalveaolar lavage or viral culture depending on medical urgency. Endpoints We will present demographics, intraoperative challenges, primary graft dysfunction, postoperative complications, survival and functional outcomes of patients with COVID-19 ARDS who underwent lung transplantation. Additionally, referral patterns, reasons for listing denial and waitlist outcomes will be presented. So far, this collaborative group has transplanted 17 patients. There have been no deaths on the waitlist, there was one post-transplant mortality at day 61. Ten patients have been discharged from the hospital and are doing well. Six patients are recovering well however less than 30 days post-transplantation and remain admitted.

(1)

International Experience with Lung Transplantation for COVID-19 Associated Acute Respiratory Distress Syndrome T.N. Machuca, 1 A. Bharat, 2 C. Kurihara, 2 R. Garza-Castillon Jr, 2 S. Kim, 2 A. Manerikar, 2 A. Pelaez, 3 M. Pipkin, 3 A. Shahmohammadi, 3 M. Rackauskas, 3 S. KG, 4 K. Balakrishnan, 4 A. Jindal, 4 L. Schaheen, 5 S. Hashimi, 5 B. Bhuddhdev, 5 A. Arjuna, 5 L. Rosso, 6 A. Palleschi, 6 C. Lang, 7 P. Jaksch, 7 M. Nosotti, 6 and K. Purpose: The COVID-19 pandemic has infected millions of people across the world and caused several thousands of deaths. Given advances in extracorporeal life support technology, ECMO for COVID-19 acute respiratory distress syndrome (ARDS) has proven to be successful in sustaining life, however, has left a significant number of patients fully depended on devices and incapable of being weaned. Lung transplantation, as a well-established therapy for end-stage lung disease, has been considered for some patients with COVID-19 ARDS in the absence of lung recovery and the presence of findings suggestive of end-stage lung disease. Methods: This is an International collaborative effort to assess the role of lung transplantation in COVID-19 ARDS. There is worldwide representation with centers from US (3), Europe (2) and Asia (1). Patients with COVID-19 ARDS supported on ECMO and/or mechanical ventilation who were deemed unweanable and developed features of end-stage lung disease were evaluated for lung transplantation. We followed ISHLT conventional recipient selection criteria recommendations and a 2 negative COVID-19 PCRs from bronchoalveaolar lavage or viral culture depending on medical urgency. Endpoints: We will present demographics, intraoperative challenges, primary graft dysfunction, postoperative complications, survival and functional outcomes of patients with COVID-19 ARDS who underwent lung transplantation. Additionally, referral patterns, reasons for listing denial and waitlist outcomes will be presented. So far, this collaborative group has transplanted 17 patients. There have been no deaths on the waitlist, there was one post-transplant mortality at day 61. Ten patients have been discharged from the hospital and are doing well. Six patients are recovering well however less than 30 days post-transplantation and remain admitted. Purpose: Inhaled pulmonary vasodilators (iPVD) are commonly used to lower PVR to modify the risk of acute RV failure in durable LVAD implantation or orthotopic heart transplantation (OHT). While inhaled nitric oxide (iNO) is the iPVD gold standard, inhaled epoprostenol (Veletri Ò ) has been introduced as a cost-conscious alternative without high-grade evidence. Thus, we conducted an investigation to primarily determine if inhaled epoprostenol is equivalent to iNO in the ability to modify acute RVF after advanced heart failure therapies. Methods: Our group has enrolled 232 patients (LVAD, N=100; OHT, N=132) in a triple-blinded (clinician, subject, statistician) randomized controlled trial conducted between May 2017-October 2020 (NCT03081052). Participants were grouped into strata according to key clinical prognostic features. Within each stratum, subjects were assigned either iNO or inhaled epoprostenol via 1:1 randomization. To assess equivalency between the two treatment arms for our primary outcome analysis, we will calculate absolute and relative risk estimates and corresponding confidence intervals (CI). If the CI do not contain the margin of difference (15%), then we will conclude there is sufficient evidence that the risk of the primary outcome in each treatment arm is similar. For each secondary outcome, we will construct univariable effect estimates and corresponding CI, which will allow for assessment of difference between treatment arms. In the case that patients have switched to the other treatment arm, we will perform an intent-to-treat (ITT) analysis without reclassifying treatment assignment. To verify ITT results, we will perform a per-protocol analysis. Endpoints: Primary.LVAD: Moderate or Severe RVF (defined by INTER-MACS, up to 21-days after surgery); OHT: PGD-RV treated with RVAD or VA-ECMO, up to 30-days after surgery. Secondary. Duration of postoperative mechanical ventilation, iPVD duration/cost, ICU and hospital lengths-of-stay, postoperative acute kidney injury, and 30-day mortality.

First Results of Soprano: Macitentan in Patients (pts) with Pulmonary Hypertension (PH) Post-Left Ventricular Assist Device (LVAD) Implantation

12 R. Zolty, 13 M

Heart & Vascular Institute, 1053-2498/$ -see front matter